Abstract
Introduction: Therapeutic drug monitoring of imatinib is widely performed to individualize imatinib dosage. While N-desmethyl imatinib is an active metabolite of imatinib, its concentrations are not routinely determined. Methods: Imatinib and N-desmethyl imatinib trough plasma concentrations at steady-state were obtained from 295 patients with either chronic myeloid leukemia or gastrointestinal stromal tumor to see whether N-desmethyl imatinib provided additional information. Pharmacokinetic data were analyzed using a nonlinear mixed effect approach. Correlations between several pharmacokinetic metrics of drug exposure were evaluated. Results: The mean value of the N-desmethyl imatinib/imatinib ratio of trough concentrations was 0.31 with half of the values between 0.23 and 0.37. N-desmethyl imatinib and total (i.e., N-desmethyl imatinib plus imatinib) trough plasma concentrations or area under the curve values were closely correlated with imatinib values. The distribution of imatinib or total concentrations between patients requiring imatinib dosage adjustment, or not, was similar. Conclusion: These results do not clearly support routine N-desmethyl monitoring since it does not provide additional information to imatinib data.
Journal Section:
Anticancer Section / Original Paper
References
1.
Verheijen
RB
, Yu
H
, Schellens
JHM
, Beijnen
JH
, Steeghs
N
, Huitema
ADR
. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology
. Clin Pharmacol Ther
. 2017
;102
(5
):765
–76
. 2.
Clarke
WA
, Chatelut
E
, Fotoohi
AK
, Larson
RA
, Martin
JH
, Mathijssen
RHJ
, et al. Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology consensus guidelines for imatinib therapy
. Eur J Cancer
. 2021
;157
:428
–40
. 3.
Baccarani
M
, Dreyling
M
; ESMO Guidelines Working Group
. Chronic myelogenous leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
. Ann Oncol
. 2009
;20
(Suppl 4
):iv105
–7
. 4.
Demetri
GD
, von Mehren
M
, Blanke
CD
, Van den Abbeele
AD
, Eisenberg
B
, Roberts
PJ
, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
. N Engl J Med
. 2002
;347
(7
):472
–80
. 5.
Demetri
GD
, Wang
Y
, Wehrle
E
, Racine
A
, Nikolova
Z
, Blanke
CD
, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors
. J Clin Oncol
. 2009
;27
(19
):3141
–7
. 6.
Picard
S
, Titier
K
, Etienne
G
, Teilhet
E
, Ducint
D
, Bernard
MA
, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
. Blood
. 2007
;109
(8
):3496
–9
. 7.
Larson
RA
, Druker
BJ
, Guilhot
F
, O’Brien
SG
, Riviere
GJ
, Krahnke
T
, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
. Blood
. 2008
;111
(8
):4022
–8
. 8.
Von Mehren
M
, Widmer
N
. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic Gastrointestinal Stromal Tumor (GIST): an emerging role for drug blood level testing
. Cancer Treat Rev
. 2011
;37
(4
):291
–9
. 9.
Larson
RA
, Chia
YL
, Granvil
C
, Guilhot
F
, Druker
BJ
, Md
SGO
, et al. Steady-state imatinib trough levels as well as dose interruptions are associated with clinical response (CCyR and MMR) and Adverse Events (AEs) in patients with Chronic Myeloid Leukemia (CML) receiving IM as frontline therapy
. Blood
. 2009
;114
(22
):2213
. 10.
Guilhot
F
, Hughes
TP
, Cortes
J
, Druker
BJ
, Baccarani
M
, Gathmann
I
, et al. Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial
. Haematologica
. 2012
;97
(5
):731
–8
. 11.
Gschwind
H-P
, Pfaar
U
, Waldmeier
F
, Zollinger
M
, Sayer
C
, Zbinden
P
, et al. Metabolism and disposition of IMATINIB mesylate in healthy volunteers
. Drug Metab Dispos
. 2005
;33
(10
):1503
–12
. 12.
Le Coutre
P
, Kreuzer
KA
, Pursche
S
, Bonin
M
, Leopold
T
, Baskaynak
G
, et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588
. Cancer Chemother Pharmacol
. 2004
;53
(4
):313
–23
. 13.
Marangon
E
, Citterio
M
, Sala
F
, Barisone
E
, Lippi
AA
, Rizzari
C
, et al. Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias
. Cancer Chemother Pharmacol
. 2009
;63
(3
):563
–6
. 14.
Huang
X
, Liu
Y
, Chen
J
, Zheng
H
, Ding
Y
, He
Z
. Therapeutic drug monitoring of imatinib and N -desmethyl imatinib in chronic myeloid leukemia patients using LC-MS/MS in a cohort study
. J Clin Pharmacol
. 2023
;63
(12
):1438
–47
. 15.
Menon-Andersen
D
, Mondick
JT
, Jayaraman
B
, Thompson
PA
, Blaney
SM
, Bernstein
M
, et al. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults
. Cancer Chemother Pharmacol
. 2009
;63
(2
):229
–38
. 16.
Petain
A
, Kattygnarath
D
, Azard
J
, Chatelut
E
, Delbaldo
C
, Geoerger
B
, et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults
. Clin Cancer Res
. 2008
;14
(21
):7102
–9
. 17.
Delbaldo
C
, Chatelut
E
, Ré
M
, Deroussent
A
, Séronie-Vivien
S
, Jambu
A
, et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors
. Clin Cancer Res
. 2006
;12
(20 Pt 1
):6073
–8
. 18.
Peng
B
, Dutreix
C
, Mehring
G
, Hayes
MJ
, Ben-Am
M
, Seiberling
M
, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion
. J Clin Pharmacol
. 2004
;44
(2
):158
–62
. 19.
Gandia
P
, Arellano
C
, Lafont
T
, Huguet
F
, Malard
L
, Chatelut
E
. Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed
. Cancer Chemother Pharmacol
. 2013
;71
(2
):531
–6
. 20.
Houk
BE
, Bello
CL
, Poland
B
, Rosen
LS
, Demetri
GD
, Motzer
RJ
. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
. Pharmacol
. 2010
;66
(2
):357
–71
. 21.
Yu
H
, Steeghs
N
, Kloth
JSL
, de Wit
D
, van Hasselt
JGC
, van Erp
NP
, et al. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU 12662
. Br J Clin Pharmacol
. 2015
;79
(5
):809
–19
. 22.
Peng
B
, Lloyd
P
, Schran
H
. Clinical pharmacokinetics of imatinib
. Clin Pharmacokinet
. 2005
;44
(9
):879
–94
. 23.
Liu
M
, Guo
T
, Ma
Z
, Du
L
, Hou
J
, Tian
Y
, et al. Correlation between N-demethyl imatinib trough concentration and serious adverse reactions in patients with gastrointestinal stromal tumors: a retrospective cohort study
. Ther Drug Monit
. 2024
;46
(3
):344
–50
. 24.
Dutreix
C
, Peng
B
, Mehring
G
, Hayes
M
, Capdeville
R
, Pokorny
R
, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
. Cancer Chemother Pharmacol
. 2004
;54
(4
):290
–4
. 25.
Bolton
AE
, Peng
B
, Hubert
M
, Krebs-Brown
A
, Capdeville
R
, Keller
U
, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects
. Cancer Chemother Pharmacol
. 2004
;53
(2
):102
–6
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
